SystImmune

Subsidiary of Sichuan Baili Pharmaceutical (688506)

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 2/3
CD33Antibody–drug conjugate
Acute Myeloid Leukemia
Phase 1
HER2Antibody–drug conjugate
Non-Small Cell Lung Cancer

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

26 February 2026Topline resultIzalontamab brengitecanPhase III BL-B01D1-307 interim topline: iza-bren met dual primary endpoints (PFS and OS) in TNBC
CN · Sichuan Biokin Pharmaceutical (SystImmune parent) · Source ↗

Financial reports

No financial reports recorded.